指南与共识贫血与红细胞疾病造血干细胞移植与细胞治疗

美国血液学会2026年重型和极重型获得性再生障碍性贫血诊疗指南

American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia.
指南 / 共识 · Blood Adv · 2026-01-01

美国血液学会组织多学科专家组,基于系统评价和GRADE方法制定重型和极重型免疫性获得性再生障碍性贫血诊疗指南,共形成33条推荐和4条良好实践声明,涵盖诊断检查、治疗策略和支持治疗。推荐强调年轻且有匹配同胞或无关供者者优先行造血干细胞移植,免疫抑制治疗失败后移植作为二线选择,并在免疫抑制方案中加入艾曲泊帕及对中性粒细胞减少患者进行抗细菌和抗真菌预防。多数临床问题的证据确定性为低或极低。

要点

  • 年轻且有匹配同胞或无关供者者优先行造血干细胞移植。
  • 移植也可作为免疫抑制治疗失败后的二线选择。
  • 推荐在免疫抑制方案中加入艾曲泊帕。

核心结论

  • 推荐年轻且有匹配同胞或无关供者的患者优先行造血干细胞移植,移植也可作为免疫抑制治疗失败后的二线选择。
  • 推荐在免疫抑制方案中加入艾曲泊帕,并对中性粒细胞减少患者使用抗细菌和抗真菌预防。

研究设计与样本

  • ASH组建了由内容专家、方法学家和患者代表组成的多学科指南专家组。
  • 证据综合团队开展系统证据评价,专家组优先确定临床问题并采用GRADE方法(含证据到决策框架)评估证据并形成推荐,推荐经公开征求意见。

主要发现

  • 专家组就诊断检查、治疗策略和支持治疗达成33条推荐和4条良好实践声明。
  • 额外推荐涵盖将艾曲泊帕纳入免疫抑制方案以及对高风险患者使用抗菌预防。
  • 多数临床问题的证据确定性被评为低或极低,主要因依赖小型非随机研究。

关键数值与推荐

  • 共形成33条推荐和4条良好实践声明。
  • 多数临床问题的证据确定性为低或极低。

临床怎么用

  • 对年轻且有匹配同胞或无关供者的患者优先考虑造血干细胞移植。
  • 免疫抑制治疗失败后可将移植作为二线选择。
  • 在免疫抑制方案中加入艾曲泊帕。
  • 对中性粒细胞减少患者使用抗细菌和抗真菌预防。

局限性

  • 多数临床问题的证据确定性为低或极低,主要因依赖小型非随机研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aplastic anemia is a rare, life-threatening condition marked by pancytopenia and bone marrow hypocellularity. Despite therapeutic advances, clinical practice remains variable, and uncertainties persist regarding diagnosis and optimal management. To address these gaps, the American Society of Hematology (ASH) developed evidence-based guidelines to provide standardized, patient-centered recommendations. OBJECTIVE: The recommendations are intended to support patients, clinicians, and other health care professionals in their decisions about the management and diagnosis of severe and very severe immune-acquired aplastic anemia. METHODS: ASH formed a multidisciplinary guideline panel of content experts, methodologists, and a patient representative. An evidence synthesis team supported the guideline development process by conducting systematic evidence reviews. The panel prioritized clinical questions and used the grading of recommendations assessment, development, and evaluation approach, including the evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 33 recommendations and 4 good practice statements addressing the use of diagnostic tests, treatment strategies and supportive care. Additional recommendations covered the incorporation of eltrombopag into immunosuppressive regimens and the use of antimicrobial prophylaxis for patients at high risk. For most clinical questions, the certainty in the evidence was rated as low or very low, largely due to the reliance on small, nonrandomized studies. CONCLUSIONS: Recommendations emphasize prioritizing hematopoietic cell transplantation for younger individuals with an available matched sibling or unrelated donor and as a second-line option after failure of immunosuppressive therapy. The panel also recommended adding eltrombopag to immunosuppressive regimens and using antibiotic and antifungal prophylaxis for patients with neutropenia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Scheinberg P, O'Neal DA, Basquiera AL, et al. American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia. Blood Adv. 2026. PMID: 41920091. doi:10.1182/bloodadvances.2025019051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。